Will combining GSK and Pfizer HIV businesses boost new therapies?
This article was originally published in Scrip
Executive Summary
In an effort to become the market leader for HIV, GlaxoSmithKline and Pfizer have merged their antiretroviral portfolios to create a so-far unnamed London-based speciality company led by GSK's Dr Dominique Limet, with 11 marketed products and another six in the clinical pipeline.